



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |  |
|--|--|--|--|
| (51) International Patent Classification:<br><br>Not classified  |  | A2   | (11) International Publication Number: <b>WO 90/11676</b><br><br>(43) International Publication Date: 18 October 1990 (18.10.90) |
| <p>(21) International Application Number: PCT/US90/01864</p> <p>(22) International Filing Date: 5 April 1990 (05.04.90)</p> <p>(30) Priority data:<br/>334,459 6 April 1989 (06.04.89) US</p> <p>(71) Applicant: CENTOCOR, INC. [US/US]; 244 Great Valley Parkway, Malvern, PA 19355 (US).</p> <p>(72) Inventors: DADDONA, Peter, E. ; 642 Marydell Drive, West Chester, PA 19380 (US). BERGER, Harvey, J. ; 687 Wetherby Lane, Devon, PA 19333 (US). McEVER, Rodger, P. ; 1716 Guilford Lane, Oklahoma City, OK 73120 (US).</p> |  | <p>(74) Agents: DECONTI, Giulio, A., Jr. et al.; Hamilton, Brook, Smith &amp; Reynolds, Two Militia Drive, Lexington, MA 02173 (US).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p><b>Published</b><br/> <i>With declaration under Article 17(2)(a).<br/> Without classification and without abstract; title not checked by the International Searching Authority.</i></p> |  |
| <p><b>(54) Title:</b> METHOD FOR IMAGING ATHEROSCLEROTIC PLAQUE</p>  |  |  |  |

### **DESIGNATIONS OF "DE"**

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### **FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                              |    |  |    |                          |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria                      | ES | Spain                                    | MG | Madagascar               |
| AU | Australia                    | FI | Finland                                  | ML | Mali                     |
| BB | Barbados                     | FR | France                                   | MR | Mauritania               |
| BE | Belgium                      | GA | Gabon                                    | MW | Malawi                   |
| BF | Burkina Faso                 | GB | United Kingdom                           | NL | Netherlands              |
| BG | Bulgaria                     | HU | Hungary                                  | NO | Norway                   |
| BJ | Benin                        | IT | Italy                                    | RO | Romania                  |
| BR | Brazil                       | JP | Japan                                    | SD | Sudan                    |
| CA | Canada                       | KP | Democratic People's Republic<br>of Korea | SE | Sweden                   |
| CF | Central African Republic     | KR | Republic of Korea                        | SN | Senegal                  |
| CG | Congo                        | LJ | Liechtenstein                            | SU | Soviet Union             |
| CH | Switzerland                  | LK | Sri Lanka                                | TD | Chad                     |
| CM | Cameroon                     | LJ | Luxembourg                               | TG | Togo                     |
| DE | Germany, Federal Republic of | MC | Monaco                                   | US | United States of America |
| DK | Denmark                      |    |  |    |                          |

-1-

METHODS FOR IMAGING ATHEROSCLEROTIC PLAQUE

Description

Background of the Invention

05 A generally accepted theory of development of atherosclerotic plaque is based on injury to the endothelial cells which line the inside surface of a blood vessel. The initial injury can be caused by chemical factors related to chronically elevated 10 levels of cholesterol in the blood or by mechanical stress associated with hypertension.

The clinical effects of atherosclerotic plaque are due to its space occupying characteristics which lead to stenosis (narrowing) or its thrombogenic 15 (clot-causing) characteristics which appear related to rupture of the fibrous cap and the resulting ulceration of the plaque surface. As a result, a thrombus will form at the site of the plaque. This, in turn, will almost invariably lead to acute 20 myocardial infarction if present in coronary arteries. See Friedman *et al.*, Am. J. Pathol., 48:19-25 (1966); Schwartz, C.J. Atherosclerosis, 15:1-4 (1972).

It appears that the first stage of plaque 25 formation is caused by macrophages migrating through the injured endothelium and accumulating subendothelial. The lesion is enlarged by an accumulation of smooth muscle cells which combine with the macrophages to form foam cells in fatty streaks. 30 Endothelial cells appear to then separate, exposing

-2-

much of the fatty streak to the circulation. This 05 ulcerated condition provides opportunities for platelet aggregation and mural thrombosis. Damage to the endothelium and the resulting platelet activation may also cause further enlargement of the plaque.

The important consequence of these effects is reduction of blood flow to the affected organ (heart, brain, etc.). Atherosclerosis is the 10 underlying cause of 75% of the one million deaths from cardiovascular disease in the United States each year. Atherosclerosis accounts for a large proportion of heart attacks, many strokes, most aneurisms of the lower abdominal aorta, and many 15 cases of peripheral vascular disease. Myocardial infarcts have been imaged with antibodies that localize at the infarct site. See, e.g., Haber *et al.*, U.S. Patent 4,036,945. A need exists for imaging methods of high reliability and high 20 resolution that can be used for diagnosing and monitoring atherosclerotic lesions. This is especially true for those lesions that have ulcerated or fissured, resulting in formation of blood clots.

25 Summary of the Invention

This invention pertains to an method of imaging atherosclerotic plaques *in vivo*. The method entails the use of monoclonal antibodies specific for activated platelets or activated endothelial 30 cells. According to the method of this invention, a

- 3 -

radiolabeled monoclonal antibody or antibody  
fragment specific for activated platelets, such as  
the monoclonal antibody S12 which is specific for  
the GMP-140 glycoprotein of activated platelets or  
05 activated endothelial cells, is administered to a  
patient suspected of having an endothelial injury  
such as an ulcerated atherosclerotic lesion. The  
radiolabeled monoclonal antibody is allowed to  
accumulate at the site of the plaque. Thereafter,  
10 the signal generated by the radiolabel is detected  
by a photoscanning device and the signal is  
converted to an image of the atherosclerotic plaque.

Brief Description of Figures

Figure 1 shows schematic representations of  
15 planar imaging of technetium-99m (Tc-99m) S12 Fab'  
in rabbits. The increasing intensity of radiolabel  
uptake is shown by the direction of the arrow in the  
figure legend.

Figure 1A shows a schematic diagram of Tc-99m  
20 S12 Fab' uptake and distribution in a control  
rabbit.

Figure 1B shows a schematic diagram of Tc-99m  
S12 Fab' uptake and distribution in an  
atherosclerotic rabbit with repeat endothelial  
25 injury.

Figure 2 shows a schematic diagram of Tc-99m  
S12 Fab' uptake and localization in the aorta of an  
atherosclerotic rabbit.

Figure 3 shows a schematic representation of  
30 Tc-99m S12 Fab' uptake and distribution in the

-4-

excised aorta of the same rabbit as shown in the previous Figure.

Detailed Description of the Invention

An immunoscintigraphic image of an atherosclerotic plaque can be obtained with radiolabeled antibodies specific for activated platelets or activated endothelial cells. An antibody or antibody fragment (antigen binding fragment) specific for activated platelets or activated endothelial cells conjugated to a label which generates a signal detectable by external scintigraphy is administered to a patient suspected of having an atherosclerotic plaque. Sufficient time is allowed for the labeled antibody to localize at the site or sites of plaque. The signal generated by the label is detected by a photoscanning device and the signal is then converted to an image of the atherosclerotic plaque.

Preferred antibodies for plaque imaging are specific for an epitope of the GMP-140 protein, a marker of activated platelets. The protein is localized in alpha-granule membranes in unstimulated platelets. After thrombin stimulation and membrane fusion, the protein is redistributed to the cell surface and plasma membrane. The protein, GMP-140 has been described by Stenberg *et al.*, J. Cell Biol., 101, 880 (1985).

In addition to being highly specific for activated platelets, antibodies specific for the GMP-140 glycoprotein have another advantage. The

-5-

antibodies also react with endothelial GMP-140. Endothelial GMP-140, like its platelet counterpart, is localized to the membranes of secretory storage granules in unstimulated endothelial cells. When 05 these cells are activated, the protein redistributes to the cell surface, just as it does in activated platelets. Thus, GMP-140 can serve a role as a marker of activated endothelial cells damaged by atherosclerotic ulceration or other endothelial 10 injury. Imaging methods of this invention employing platelet-specific monoclonal antibodies are able to detect sites of endothelial injury in which vascular lesions are associated with platelet activation. These ulcerated or ruptured sites of plaque 15 formation can be detected using platelet-specific monoclonal antibodies.

A particularly preferred antibody for the method of this invention is the monoclonal antibody S12 which reacts specifically with the GMP-140 20 protein. The S12 antibody reacts minimally with unstimulated human platelets but binds extensively after platelets have been activated with thrombin. See McEver and Martin, J. Biol. Chem., 259:9799 (1984) incorporated herein by reference.

25 Antibodies against components of activated platelets other than GMP-140 may also be used. For example, the monoclonal antibody Tab, which binds to platelet glycoprotein IIb, can also be used in embodiments of this invention. See McEver et al., 30 J. Biol. Chem., 258:5269 (1983), incorporated herein by reference.

GMP-140 specific monoclonal antibodies of this invention are produced by hybrid cell lines commonly known as hybridomas. These hybrid cells are formed by fusion of an anti-GMP-140 antibody-producing cell 05 and an immortalizing partner (i.e. a cell line which imparts long term tissue culture stability to the hybrid cell). In the formation of the hybrid cell lines, the anti-GMP-140 antibody-producing cell can be a B lymphocyte obtained from an animal or human 10 who has developed an immune response to GMP-140: (i) naturally; (ii) as a result of a pathologic process; (iii) as a consequence of having been immunized with material containing GMP-140 such as activated platelets, activated endothelial cells, or a 15 biological preparation comprising GMP-140. The immortalizing partner can be a cell of B lymphocyte lineage such as a B lymphoblastoid cell line or a plasmacytoma cell such as a myeloma cell, itself a antibody producing cell that is also malignant.

20 In particular, murine hybridomas producing GMP-140-specific monoclonal antibodies are formed by fusion of: (i) mouse myeloma cells and (ii) spleen cells from mice immunized against GMP-140 positive platelets or endothelial cells, purified GMP-140, or 25 other biological preparations containing GMP-140. Fusions are accomplished by standard procedures well known in the art. Kohler and Milstein, Nature, 256, 495-497 (1975) and Kennet, Monoclonal Antibodies (Kennet et. al., eds.), pp. 365-367, Plenum Press, 30 N.Y. 1980). The resulting murine hybridoma clones are then screened for production of antibody

-7-

reactive with GMP-140-positive platelets, endothelial cells, or preparations containing GMP-140. Those which secrete antibodies of the appropriate reactivity and specificity are cloned to 05 yield a homogeneous cell line secreting anti-GMP-140 antibody.

Human hybridomas which produce monoclonal anti-GMP-140 antibodies are formed from the fusion of: (i) human B cells from an individual producing 10 anti-GMP-140 antibodies and (ii) human B lymphoblastoid or human/human-mouse myeloma cells. The fusion partner for the myeloma cell may be an anti-GMP-140-producing B lymphocyte derived from the blood, spleen, or tonsil lymph node. The fusion and 15 screening techniques are essentially the same as those used in the production and screening of murine anti-GMP-140 generating hybridomas.

Mouse/human hybridomas which produce human anti-GMP-140 antibody can be formed from the fusion 20 of human antibody-producing cells and a murine plasmacytoma cell or a cell which itself is a hybrid having the appropriate properties such as the ability to fuse with human lymphocytes at a high frequency; support the synthesis and secretion of 25 high levels of antibody; and support secretion of antibody for prolonged periods of time in culture.

Another way of forming the anti-GMP-140-producing cell line is by transformation of antibody-producing cells. For 30 example, an anti-GMP-140 producing B lymphocyte may be infected and transformed with a virus such as

- 8 -

Epstein-Barr virus to yield an immortal anti-GMP-140 producing cell. Kozbor and Roder, Immunology Today, 4, 72-79 (1983). Alternatively, the B lymphocyte may be transformed by a transforming gene or gene product.

05 GMP-140-specific monoclonal antibodies are produced in large quantities by injecting anti-GMP-140 antibody-producing hybridomas into the peritoneal cavity of mice or other appropriate hosts 10 and, after appropriate time, harvesting the resulting ascitic fluid which contains a high titer of antibody, and isolating the desired anti-GMP-140 monoclonal antibody therefrom. Allogeneic or xenogeneic hybridomas can be injected into 15 immunosuppressed, irradiated or athymic nude mice. Alternatively, the antibodies may be produced by culturing anti-GMP-140 producing cells in vitro and isolating secreted monoclonal anti-GMP-140 antibodies from the cell culture medium.

20 Antibody fragments, rather than whole antibody molecules, are generally preferred for use in the plaque-imaging method of this invention. Because they are distributed more readily in the tissues than are entire antibody molecules, antibody 25 fragments accumulate at the target site more rapidly. Thus an image can be obtained in less time than is possible using whole antibody. These fragments are also cleared more rapidly from the circulation, resulting in a lower background signal. 30 Haber et al., U.S. Patent No. 4,036,945; Goldenberg et al., U.S. Patent No. 4,331,647. The antigen

-9-

binding fragments  $F_v$ , Fab, Fab' and  $F(ab')_2$  or analogs of these fragments can be used. The Fab fragment can be prepared by digestion of whole immunoglobulin molecules with the enzyme papain; the 05  $F(ab')_2$  fragment can be prepared by digestion of the whole immunoglobulin molecule with pepsin; and the Fab' fragment produced from the  $F(ab')_2$  fragment by reduction with dithiothreitol or cysteine, according to any of several well known protocols. In 10 addition, fragments can also be prepared by recombinant DNA techniques. See, for example, U.S. Patent Application Serial No. 195,720 (Coller and Knight), filed May 18, 1988, the teachings of which are incorporated by reference herein.

15 The antibodies or antibody fragments can be labeled with radioisotopes such as Indium-111 and Technetium-99m which are suitable for detection by external scintigraphy. The gamma-emitters Indium-111 and Technetium-99m are preferred because 20 these radiometals are detectable with a gamma camera and have favorable half-lives *in vivo*. Technetium-99m is an ideal radionuclide for scintigraphic imaging because of its nuclear properties. It has a single photon energy of 140 KeV, a half-life of 25 about 6 hours, and it is readily available from a  $^{99}\text{Mo}$ - $^{99}\text{mTc}$  generator.

Antibodies can be labeled by any of the many techniques known in the art. The preferred technique for technetium-99m labelling is that of 30 Pak, K.Y et al., United States Patent Application Serial No. 034,003, filed April 2, 1987, the

-10-

teachings of which are incorporated herein.

Antibody can also be labeled with a radiometal via a chelating agent such as diethylene-triaminepentaacetic acid (DTPA) which is conjugated

05 to the antibody. In this indirect labeling approach, the radiometal is chelated by the chelating agent attached to the antibody. See, for example, Khaw *et al.*, Science, 209:295-297 (1980) Krejcarek and Tucker, Biochem. Biophys. Res. Commun., 77:581-585 (1977); Childs, and Hnatowich, J. Nucl. Med., 26:293 (1985).

10 Various subtraction techniques can be used to enhance detection and/or localization of labeled antibodies. See, for example, Ballou, B. *et al.*, Science, 206:844-847 (1979), and references cited 15 therein.

20 The labeled antibody is administered to a patient in the form of an injectable composition. Injection may be intravenous or intraarterial. A typical composition contains a quantity of radiolabeled antibody sufficient for imaging (e.g., specific activity 3-150 mCi/mg) in neutral phosphate buffer containing physiological saline.

25 Photoscanning can be performed by standard techniques. Goldenberg *et al.*, New Engl. J. Med., 298:1389 (1978) and references cited therein.

30 The method of this invention can be used to distinguish between ulcerated and nonulcerated atherosclerotic plaque. The method is clinically useful for monitoring the extent of progression of atherosclerosis in heart attack survivors and in

-11-

screening a population at risk for atherosclerosis (about 143 million worldwide). Information provided by the methods of this invention will aid physicians in evaluation of therapy and in early diagnosis of  
05 atherosclerotic plaque.

This invention will now be more fully disclosed according to the following examples.

Example I: Preparation of Technetium 99m-labeled anti-platelet Fab' fragment

10 A. Preparation of S12 Fab'

S12 IgG is purified from hybridoma tissue culture supernatant using Protein A Sepharose column chromatography. The  $F(ab')_2$  fragment is prepared from the IgG by pepsin proteolytic digestion at pH  
15 3.9 and subsequently purified by cation exchange chromatography using for example, Pharmacia Fast Flow S. The Fab' fragment is produced from the  $F(ab')_2$  by reduction with dithiothreitol, purified by diafiltration or column gel filtration and  
20 formulated at 1-2 mg/ml in 50mM sodium phosphate buffer pH 6.3 containing 100mM sodium chloride and 1mM EDTA.

B. Labeling of S12 Fab' with Tc-99m

The S12 Fab' antibody fragment is labeled with  
25 Technetium 99m as described by Pak et al., Circulation 76 Supplement II, #2013 (1987); Pak et al U.S. Patent Application Serial No. 034,003 (filed April 2, 1987). Using D-glucarate as the transfer ligand, 200-400  $\mu$ g aliquots of the Fab' are labeled

-12-

with Tc-99m to a specific activity of 10-40 mCi/mg. Final protein concentrations are 0.5 - 1 mg/ml in the labeling solution. The quantitative incorporation of Tc-99m is determined by gel 05 filtration HPLC equipped with a radiometric detector, ITLC and paper chromatography.

Immunoactivity of Tc-99m S12 Fab' is evaluated using a platelet binding assay with thrombin-activated or unactivated platelets.

10 In this method, platelets are isolated by differential centrifugation from ACD treated whole human blood taken from normal volunteers. In the assay a fixed number of washed platelets ( $5 \times 10^7$ /ml) in PBS with 1% bovine serum albumin (BSA) is 15 incubated with varying concentrations of Tc-99m S12 Fab' or Tc-99m labeled control antibody in PBS with BSA, 1 mM EDTA (final conc.) to prevent platelet aggregation and 8 units/ml of bovine thrombin (final conc.). Thrombin is omitted from the assay when 20 binding to resting platelets is evaluated. Incubations are performed at room temperature for 60-120 min. Platelets are washed by centrifugation and radioactivity bound to platelets determined using a gamma counter set for Tc-99m.

25 Specific saturable binding of Tc-99m S12 Fab' has been demonstrated using this assay. The specificity of binding is such that 200 ug/mL of unlabeled S12 IgG prevents the binding of Tc-99m S12 Fab' to attached platelets. The binding is also 30 activation dependent since there is only a background level of binding in this assay using

-13-

platelets which have not been exposed to thrombin. The labeled S12 Fab' reacts strongly with activated platelets isolated from human, baboon, and rabbit. The antibody shows weak to no reactivity with 05 unactivated platelets from these same species.

Example II: Imaging using Tc-99m S12 Fab'  
monoclonal antibody

A. Preparation of a Rabbit Atherosclerosis Model

Rabbits weighing 5-10 lbs. received a 2% 10 cholesterol atherogenic diet in order to elevate serum cholesterol levels. The diet consisted of rabbit chow supplemented by cholesterol-enriched peanut oil to produce hypercholesterolemia (cholesterol = 500-1000 mg %). This control group 15 was kept on the diet for 1-2 weeks. A more severe atherosclerotic condition was induced in the test group using the Baumgartner technique. Baumgartner H.R., Ges. Exp. Med. 137, 227, (1963). In brief, the endothelial lining of the infra-renal aorta is 20 stripped or denuded by percutaneous placement of a 4 French Fogarty catheter via a femoral arteriotomy under sterile conditions. The catheter is retrogradely advanced through the iliac artery under 25 fluoroscopic guidance. The balloon tip is inflated with saline and then drawn three times from the level of the renal to the proximal right iliac artery. After endothelial injury, the high cholesterol atherogenic diet is continued for an 30 additional 4-6 weeks until the arterial re-injury phase of the study. This model has previously been

-14-

shown to cause significant atherosclerosis characterized by intimal thickening, foam cell lesions and neovascularization in 66% of the animals. Baumgartner H.R., Ges. Exp. Med.  
05 137,227(1963).

B. Tc-99m Fab' Imaging of Arterial Injury in Rabbit Atherosclerosis Model

All rabbits were modeled to have atherosclerosis of the lower aorta and proximal 10 iliac artery using a Fogarty catheter injury followed by high cholesterol diet for 4-6 weeks, as described previously. Rabbits were divided into three groups of increasingly severe aortic injury as follows:

15 I. Control group (resting plaque);  
II. Reinjury group (repeated balloon injury causing focal ruptured plaque and endothelial damage); and  
III. Percutaneous transluminal  
20 angioplasty (PTA) with intravascular stent placement (repeated balloon injury and placement of a 1cm long wire mesh stent).

At the time of each imaging study, contrast 25 angiography was performed to confirm the site of injury. Animals were not anticoagulated or pre-treated with antiplatelet medications.

-15-

Within 15 minutes of injury, each rabbit was injected with 5 mCi/400  $\mu$ g of Tc-99m S12 Fab' via an ear vein. Serial 5 minute images were obtained for 60 minutes after injection using a Searle 37 x gamma 05 camera and high resolution collimator and analyzed on a MDS A2 computer. In vivo Tc-99m S12 Fab' uptake was quantitated 45 - 60 minutes post 10 injection from planar image regions-of-interest to derive an injured to normal (I:N) aortic activity ratio. Results from the three subgroups of 10 increasingly severe injury are shown in Table 1.

-16-

Table 1

| <u>Group</u> | <u>Rabbits</u> | <u>Injury</u> | <u>S12 I:N Ratio</u> |
|--------------|----------------|---------------|----------------------|
| I.           | 4              | Control       | 1.2 ± 0.17           |
| II.          | 6              | Reinjury      | 1.5 ± 0.18           |
| 05 III.      | 3              | PTA/Stent     | 1.9 ± 0.12           |

The reinjury (II) and PTA/Stent (III) groups showed distinct focal Tc-99m S12 Fab' uptake that was significantly greater than that of control group I ( $p < 0.01$ ). Ex vivo imaging of the blood-free excised aortas confirmed marked S12 localization with an I:N =  $3.2 \pm 1.4$  at pathologically and angiographically proven injury sites.

These results demonstrate that Tc-99m S12 Fab' localizes sites of active platelet degranulation in balloon-injured atherosclerotic endothelium with high specificity. Further, the degree of S12 uptake is proportional to the severity of the arterial injury.

Intense and focal uptake of Tc-99m S12 Fab' was demonstrated in the reinjury and PTA stented atherosclerotic model relative to the control atherosclerotic rabbits using planar imaging. Fig. 1 shows a schematic diagram of the planar imaging of Tc-99m S12 Fab' in a representative control rabbit (Figure 1A) and an atherosclerotic rabbit with repeat Fogarty injury (Figure 1B). The control rabbit was imaged 35 min. after Tc-99m S12 Fab'

-17-

injection and shows non-specific radiochemical uptake in the two kidneys (upper quadrant), the spleen (left mid-section) and the bladder (lower center). Minimal uptake is visible in the descended 05 infra renal aorta (mid-line area). An atherosclerotic rabbit with Fogarty treatment (Figure 1B) shows intense radiochemical uptake in the upper infra renal aorta between the two kidneys (upper quadrant). Angiographic analysis of these 10 rabbits (not presented here) clearly reveal the bulging aorta of the atherosclerotic rabbit relative to the control.

A complete set of in vivo and ex vivo images, angiograms, x-rays and pathology pictures was taken 15 from a rabbit that received a PTA stent following atherosclerotic modeling and previous Fogarty balloon injury. Figure 2 shows a schematic diagram of the radiolocalization of the Tc-99m S12 Fab' in the descending aorta of this rabbit taken 35 minutes 20 after injection. Localization is noted as the intense streak in the area of the descending aorta. Sixty minutes after imaging, the rabbit was sacrificed, the descending aorta was excised, washed free of blood and mounted for pathological 25 examination. Visual analysis revealed a mixture of white and red thrombus in the wire mesh of the stent and extensive atherosclerosis over the entire region of the aorta. A representation of the ex vivo image of the excised aorta indicating the localization of 30 the Tc-99m S12 Fab' is shown in Figure 3. These data, taken together show an excellent correlation

-18-

of the atherosclerotic injury site by angiography, pathology and in vivo and ex vivo imaging using the Tc-99m S12 Fab' antibody.

Equivalents

05        Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed in the  
10 following claims.

-19-





CLAIMS

1. A method of imaging an atherosclerotic plaque, comprising the steps of:
  - a. administering to an individual suspected of having atherosclerotic plaque, a radiolabeled monoclonal antibody or fragment thereof, specific for activated platelets or activated endothelial cells;
  - b. allowing the radiolabeled monoclonal antibody or antibody-fragment to accumulate at the plaque site;
  - c. detecting the signal generated by the radiolabel by means of a photoscanning device;
  - d. converting the detected signal into an image of the plaque.
2. A method of Claim 1, wherein the monoclonal antibody fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, and F<sub>v</sub> fragments.
3. A method of Claim 1, wherein the monoclonal antibody is labeled with a radioactive material selected from the group consisting of Technetium-99m and Indium-111.

-20-

4. A method of Claim 1, wherein the activated platelet-specific monoclonal antibody is specific for the activated platelet membrane protein GMP-140.
- 05 5. A method of Claim 4, wherein the monoclonal antibody is S12.
6. A method of claim 1, wherein the atherosclerotic plaque is ulcerated or ruptured.
- 10 7. A method of imaging atherosclerotic plaque, comprising the steps of:
  - a. administering to an individual suspected of having atherosclerotic plaque, a  $^{99m}$ Tc-labeled Fab fragment of monoclonal antibody S12;
  - 15 b. allowing the radiolabeled antibody fragment to accumulate at the plaque site;
  - c. detecting the signal generated by means of a gamma camera;
  - 20 d. converting the detected signal into an image of the plaque.

1/1

**FIG. 1A****FIG. 1B****FIG. 2****FIG. 3**

**PATENT COOPERATION TREATY**

**DECLARATION OF NON-ESTABLISHMENT OF INTERNATIONAL SEARCH REPORT**  
 issued pursuant to PCT Article 17(2)(a)<sup>(1)</sup>

|   |   |  |
|---|---|--|
| <b>IDENTIFICATION OF THE INTERNATIONAL APPLICATION</b>  |   | <b>APPLICANT'S OR AGENT'S FILE REFERENCE</b><br>CTR88-22 |
| International Application No.   | International Filing Date               |  |
| PCT/US 90/01864   | 5th April 1990                          |  |
| Receiving Office<br>RO/US   | Priority Date Claimed<br>6th April 1989 |  |
| <b>Applicant (Name)</b><br>CENTROCOR INC.   |   |  |
| <b>DECLARATION</b>  |   |  |
| <p>This International Searching Authority hereby declares that no international search report will be established on the above-identified international application for the reasons indicated below.<sup>(1)</sup></p> <p>1. The subject matter of the international application relates to:<sup>(2)</sup></p> <p>a. <input type="checkbox"/> scientific theories.<br/>         b. <input type="checkbox"/> mathematical theories.<br/>         c. <input type="checkbox"/> plant varieties.<br/>         d. <input type="checkbox"/> animal varieties.<br/>         e. <input type="checkbox"/> essentially biological processes for the production of plants and animals, other than microbiological processes and the products of such processes.<br/>         f. <input type="checkbox"/> schemes, rules or methods of doing business.<br/>         g. <input type="checkbox"/> schemes, rules or methods of performing purely mental acts.<br/>         h. <input type="checkbox"/> schemes, rules or methods of playing games.<br/>         i. <input checked="" type="checkbox"/> methods for treatment of the human body by surgery or therapy.<br/>         j. <input type="checkbox"/> methods for treatment of the animal body by surgery or therapy.<br/>         k. <input type="checkbox"/> diagnostic methods.<br/>         l. <input type="checkbox"/> mere presentations of information.<br/>         m. <input type="checkbox"/> computer programs for which this International Searching Authority is not equipped to search prior art.</p> <p>2. The failure of the following parts of the international application to comply with prescribed requirements prevents a meaningful search from being carried out:<sup>(3)</sup></p> <p>a. <input type="checkbox"/> the description.<br/>         b. <input checked="" type="checkbox"/> the claims. Pls. see Rule 39.1 (iv) - PCT<br/>         c. <input type="checkbox"/> the drawings.</p> <p>comment:</p> |   |  |
| <b>CERTIFICATION</b>  |   |  |
| International Searching Authority<br>ISA / EP   | Date of Mailing<br>7.6.90               | Authorized Officer<br>M. FEGI M. Reg                     |